Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials

Kazuto Oya, Yuki Matsuda, Shinji Matsunaga, Taro Kishi, Nakao Iwata

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The aim of this study was to perform a systematic review and an updated and comprehensive meta-analysis of oxytocin augmentation therapy in patients with schizophrenia who received antipsychotic agents. Data published up to 07/11/2015 were obtained from PubMed, PsycINFO, and Cochrane Library databases. We conducted a systematic review and meta-analysis of patients’ data from randomized controlled trials (RCTs) comparing oxytocin with placebo. Relative risk (RR), standardized mean difference (SMD), and 95 % confidence intervals (95 % CI) based on the random-effects model were calculated. We included seven RCTs; the total sample size was 206 patients. Oxytocin was superior to placebo for decreasing the Positive and Negative Syndrome Scale (PANSS) general subscale scores (SMD = −0.44, 95 % CI −0.82 to −0.06, p = 0.02, I2 = 0 %, N = 4, n = 112); however, it was not different from placebo for total symptoms (SMD = −0.46, 95 % CI −1.20 to 0.28, p = 0.22, I2 = 80 %, N = 6, n = 162), positive symptoms (SMD = −0.18, 95 % CI −0.87 to 0.51, p = 0.60, I2 = 81 %, N = 6, n = 192), and negative symptoms (SMD = −0.34, 95 % CI −0.76 to 0.08, p = 0.12, I2 = 55 %, N = 7, n = 214). However, a sensitivity analysis including only oxytocin administration on consecutive days studies was superior to placebo in negative symptoms (SMD = −0.44, 95 % CI −0.87 to −0.01, p = 0.04, I2 = 51 %, N = 6 n = 192). There were no significant differences for all-cause discontinuation (RR = 1.02) and individual side effects such as headache and dizziness between oxytocin and placebo. Oxytocin may improve PANSS general subscale scores in schizophrenia and seems to be well tolerated. However, because the number of studies in the current analysis was small, further study will be required using larger sample sizes.

Original languageEnglish
Pages (from-to)439-450
Number of pages12
JournalEuropean Archives of Psychiatry and Clinical Neuroscience
Volume266
Issue number5
DOIs
Publication statusPublished - 01-08-2016

Fingerprint

Oxytocin
Meta-Analysis
Schizophrenia
Randomized Controlled Trials
Placebos
Confidence Intervals
Safety
Sample Size
Therapeutics
Dizziness
PubMed
Antipsychotic Agents
Libraries
Headache
Databases

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Pharmacology (medical)

Cite this

@article{1467f2d4468a4bf5b2abe46e9c9fcda3,
title = "Efficacy and safety of oxytocin augmentation therapy for schizophrenia: an updated systematic review and meta-analysis of randomized, placebo-controlled trials",
abstract = "The aim of this study was to perform a systematic review and an updated and comprehensive meta-analysis of oxytocin augmentation therapy in patients with schizophrenia who received antipsychotic agents. Data published up to 07/11/2015 were obtained from PubMed, PsycINFO, and Cochrane Library databases. We conducted a systematic review and meta-analysis of patients’ data from randomized controlled trials (RCTs) comparing oxytocin with placebo. Relative risk (RR), standardized mean difference (SMD), and 95 {\%} confidence intervals (95 {\%} CI) based on the random-effects model were calculated. We included seven RCTs; the total sample size was 206 patients. Oxytocin was superior to placebo for decreasing the Positive and Negative Syndrome Scale (PANSS) general subscale scores (SMD = −0.44, 95 {\%} CI −0.82 to −0.06, p = 0.02, I2 = 0 {\%}, N = 4, n = 112); however, it was not different from placebo for total symptoms (SMD = −0.46, 95 {\%} CI −1.20 to 0.28, p = 0.22, I2 = 80 {\%}, N = 6, n = 162), positive symptoms (SMD = −0.18, 95 {\%} CI −0.87 to 0.51, p = 0.60, I2 = 81 {\%}, N = 6, n = 192), and negative symptoms (SMD = −0.34, 95 {\%} CI −0.76 to 0.08, p = 0.12, I2 = 55 {\%}, N = 7, n = 214). However, a sensitivity analysis including only oxytocin administration on consecutive days studies was superior to placebo in negative symptoms (SMD = −0.44, 95 {\%} CI −0.87 to −0.01, p = 0.04, I2 = 51 {\%}, N = 6 n = 192). There were no significant differences for all-cause discontinuation (RR = 1.02) and individual side effects such as headache and dizziness between oxytocin and placebo. Oxytocin may improve PANSS general subscale scores in schizophrenia and seems to be well tolerated. However, because the number of studies in the current analysis was small, further study will be required using larger sample sizes.",
author = "Kazuto Oya and Yuki Matsuda and Shinji Matsunaga and Taro Kishi and Nakao Iwata",
year = "2016",
month = "8",
day = "1",
doi = "10.1007/s00406-015-0634-9",
language = "English",
volume = "266",
pages = "439--450",
journal = "Archiv fur Psychiatrie und Nervenkrankheiten",
issn = "0003-9373",
publisher = "D. Steinkopff-Verlag",
number = "5",

}

Efficacy and safety of oxytocin augmentation therapy for schizophrenia : an updated systematic review and meta-analysis of randomized, placebo-controlled trials. / Oya, Kazuto; Matsuda, Yuki; Matsunaga, Shinji; Kishi, Taro; Iwata, Nakao.

In: European Archives of Psychiatry and Clinical Neuroscience, Vol. 266, No. 5, 01.08.2016, p. 439-450.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy and safety of oxytocin augmentation therapy for schizophrenia

T2 - an updated systematic review and meta-analysis of randomized, placebo-controlled trials

AU - Oya, Kazuto

AU - Matsuda, Yuki

AU - Matsunaga, Shinji

AU - Kishi, Taro

AU - Iwata, Nakao

PY - 2016/8/1

Y1 - 2016/8/1

N2 - The aim of this study was to perform a systematic review and an updated and comprehensive meta-analysis of oxytocin augmentation therapy in patients with schizophrenia who received antipsychotic agents. Data published up to 07/11/2015 were obtained from PubMed, PsycINFO, and Cochrane Library databases. We conducted a systematic review and meta-analysis of patients’ data from randomized controlled trials (RCTs) comparing oxytocin with placebo. Relative risk (RR), standardized mean difference (SMD), and 95 % confidence intervals (95 % CI) based on the random-effects model were calculated. We included seven RCTs; the total sample size was 206 patients. Oxytocin was superior to placebo for decreasing the Positive and Negative Syndrome Scale (PANSS) general subscale scores (SMD = −0.44, 95 % CI −0.82 to −0.06, p = 0.02, I2 = 0 %, N = 4, n = 112); however, it was not different from placebo for total symptoms (SMD = −0.46, 95 % CI −1.20 to 0.28, p = 0.22, I2 = 80 %, N = 6, n = 162), positive symptoms (SMD = −0.18, 95 % CI −0.87 to 0.51, p = 0.60, I2 = 81 %, N = 6, n = 192), and negative symptoms (SMD = −0.34, 95 % CI −0.76 to 0.08, p = 0.12, I2 = 55 %, N = 7, n = 214). However, a sensitivity analysis including only oxytocin administration on consecutive days studies was superior to placebo in negative symptoms (SMD = −0.44, 95 % CI −0.87 to −0.01, p = 0.04, I2 = 51 %, N = 6 n = 192). There were no significant differences for all-cause discontinuation (RR = 1.02) and individual side effects such as headache and dizziness between oxytocin and placebo. Oxytocin may improve PANSS general subscale scores in schizophrenia and seems to be well tolerated. However, because the number of studies in the current analysis was small, further study will be required using larger sample sizes.

AB - The aim of this study was to perform a systematic review and an updated and comprehensive meta-analysis of oxytocin augmentation therapy in patients with schizophrenia who received antipsychotic agents. Data published up to 07/11/2015 were obtained from PubMed, PsycINFO, and Cochrane Library databases. We conducted a systematic review and meta-analysis of patients’ data from randomized controlled trials (RCTs) comparing oxytocin with placebo. Relative risk (RR), standardized mean difference (SMD), and 95 % confidence intervals (95 % CI) based on the random-effects model were calculated. We included seven RCTs; the total sample size was 206 patients. Oxytocin was superior to placebo for decreasing the Positive and Negative Syndrome Scale (PANSS) general subscale scores (SMD = −0.44, 95 % CI −0.82 to −0.06, p = 0.02, I2 = 0 %, N = 4, n = 112); however, it was not different from placebo for total symptoms (SMD = −0.46, 95 % CI −1.20 to 0.28, p = 0.22, I2 = 80 %, N = 6, n = 162), positive symptoms (SMD = −0.18, 95 % CI −0.87 to 0.51, p = 0.60, I2 = 81 %, N = 6, n = 192), and negative symptoms (SMD = −0.34, 95 % CI −0.76 to 0.08, p = 0.12, I2 = 55 %, N = 7, n = 214). However, a sensitivity analysis including only oxytocin administration on consecutive days studies was superior to placebo in negative symptoms (SMD = −0.44, 95 % CI −0.87 to −0.01, p = 0.04, I2 = 51 %, N = 6 n = 192). There were no significant differences for all-cause discontinuation (RR = 1.02) and individual side effects such as headache and dizziness between oxytocin and placebo. Oxytocin may improve PANSS general subscale scores in schizophrenia and seems to be well tolerated. However, because the number of studies in the current analysis was small, further study will be required using larger sample sizes.

UR - http://www.scopus.com/inward/record.url?scp=84939863948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939863948&partnerID=8YFLogxK

U2 - 10.1007/s00406-015-0634-9

DO - 10.1007/s00406-015-0634-9

M3 - Article

C2 - 26303414

AN - SCOPUS:84939863948

VL - 266

SP - 439

EP - 450

JO - Archiv fur Psychiatrie und Nervenkrankheiten

JF - Archiv fur Psychiatrie und Nervenkrankheiten

SN - 0003-9373

IS - 5

ER -